Novel measurement of rapid treatment success with ReQuest™: First and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole

Digestion

Volumn 71, Issue 3, 2005, Pages 152-158

  Mönnikes, Hubert ^a,e   Pfaffenberger, Bernd ^b   Gatz, Gudrun ^b   Hein, Jasper ^c   Bardhan, Karna Dev ^d  

^a HUMBOLDT UNIVERSITY   (Germany)

^b ALTANA PHARMA AG   (Germany)

^c Rotherham District General Hospital ^*

^d ROTHERHAM GENERAL HOSPITAL   (United Kingdom)

^e FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Endoscopy negative GERD; Gastroesophageal reflux disease, symptom relief; ReQuest

Indexed keywords

ESOMEPRAZOLE; PANTOPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGESTIVE TRACT PARAMETERS; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTICENTER STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; ENDOSCOPY, GASTROINTESTINAL; FEMALE; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; QUALITY OF LIFE; QUESTIONNAIRES; SAFETY; SEVERITY OF ILLNESS INDEX; SULFOXIDES; TREATMENT OUTCOME;

EID: 21344463807     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085576     Document Type: Article

References (30)

1. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, Lauritsen K, Reynolds JC, Shaw M, Talley NJ, on behalf of the Genval Workshop Group: An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999;44(suppl 2):S1-S16.
2. Moss SF, Armstrong D, Arnold R, Ferenci P, Fock KM, Holtmann G, McCarthy DM, Moraes-Filho JP, Mutschler E, Playford R, Spechler SJ, Stanghellini V, Modlin IM: GERD 2003 - A consensus on the way ahead. Digestion 2003;67:111-117.
3. Kahrilas PJ: Diagnosis of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003;98(3 suppl):S15-S23.
4. Fass R, Fennerty MB, Vakil N: Nonerosive reflux disease - Current concepts and dilemmas. Am J Gastroenterol 2001;96:303-314.
5. Carlsson R, Holloway RH: Endoscopy-negative reflux disease. Baillieres Best Pract Res Clin Gastroenterol 2000;14:827-837.
6. Stanghellini V, Armstrong D, Mönnikes H, Bardhan KD: Systematic review: Do we need a new gastro-oesophageal reflux disease questionnaire? Aliment Pharmacol Ther 2004;19: 463-479.
7. Pare P, Meyer F, Armstrong D, Pyzyk M, Pericak D, Goeree R: Validation of the GSFQ, a self-administered symptom frequency questionnaire for patients with gastroesophageal reflux disease. Can J Gastroenterol 2003;17: 307-312.
8. Damiano A, Handley K, Adler E, Siddique R, Bhattacharyja A: Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: Further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS). Dig Dis Sci 2002;47:1530-1537.
9. Armstrong D, Mönnikes H, Bardhan KD, Stanghellini V: The construction of a new evaluative GERD questionnaire - Methods and state of the art. Digestion 2004;70:71-78.
10. Bardhan KD, Stanghellini V, Armstrong D, Berghöfer P, Gatz G, Mönnikes H: Evaluation of GERD symptoms during therapy. Part I: Development of the new GERD questionnaire ReQuest™. Digestion 2004;69:229-237.
11. Mönnikes H, Bardhan KD, Stanghellini V, Berghöfer P, Bethke TD, Armstrong D: Evaluation of GERD symptoms during therapy. Part II: Psychometric evaluation and validation of the new questionnaire ReQuest™ in erosive GERD. Digestion 2004;69:238-244.
12. Bardhan KD, Stanghellini V, Armstrong D, Berghöfer P, Gatz G, Mönnikes H: International validation of ReQuest™ in patients with endoscopy negative gastroesophageal reflux disease. Aliment Pharmacol Ther 2004;20: 891-898.
13. Bardhan KD: Pantoprazole: A new proton pump inhibitor in the management of upper gastrointestinal disease. Drugs Today (Barc) 1999;35:773-808.
14. Spencer CM, Faulds D: Esomeprazole. Drugs 2000;60:321-329.
15. Gillessen A, Beil W, Modlin IM, Gatz G, Hole U: 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol 2004;38:332-340.
16. Simon B, Muller P, Pascu O, Gatz G, Sander P, Huber R, Mascher H: Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: A crossover study in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2003;15:791-799.
17. Scholten T, Gatz G, Hole U: Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther 2003;18:587-594.
18. Armstrong D, Pare P, Pericak D, Pyzyk M, Canadian Pantoprazole GERD Study Group: Symptom relief in gastroesophageal reflux disease: A randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 2001;96:2849-2857.
19. Talley NJ, Moore MG, Sprogis A, Katelaris P: Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. Med J Aust 2002;177:423-427.
20. Talley NJ, Venables TL, Green JR, Armstrong D, O'Kane KP, Giaffer M, Bardhan KD, Carlsson RG, Chen S, Hasselgren GS: Esomeprazole 40 and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: A placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002;14:857-863.
21. Talley NJ, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C, Schulz T, Omland TM, Delle M, Junghard O: Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001;15:347-354.
22. Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG: Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575-583.
23. Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, D'Amico D, Hamelin B, Joelsson B: Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000;14:1249-1258.
24. Stanghellini V, Armstrong D, Mönnikes H, Berghöfer P, Gatz G, Bardhan KD: Determination of ReQuest™-based symptom thresholds to define symptom relief in GERD clinical studies. Digestion 2005;71:145-151.
25. McColl E: Best practice in symptom assessment: A review. Gut 2004;53(suppl IV):iv49-iv54.
26. Dent J, Armstrong D, Delaney P, Moayyedi P, Talley NJ, Vakil N: Symptom evaluation in reflux disease: Workshop, background, processes, terminology, recommendations, and discussion outputs. Gut 2004;53(suppl IV): iv1-iv24.
27. Wiklund I: Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig Dis 2004;22:108-114.
28. Yacyshyn BR, Thomson AB: The clinical importance of proton pump inhibitor pharmacokinetics. Digestion 2002;66:67-78.
29. Moretzsohn LD, Brito EM, Reis MSF, Coelho LGV, Castro LP: Assessment of effectiveness of different dosage regimens of pantoprazole in controlling symptoms and healing esophageal lesions of patients with mild erosive esophagitis. Arq Gastroenterol 2002;39:123-125.
30. Kovacs TO, Wilcox CM, Devault K, Miska D, Bochenek W, Pantoprazole US GERD Study Group B: Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: A randomized, active-controlled, double-blindstudy. Aliment Pharmacol Ther 2002;16:2043-2052.